Elutia, Inc.Elutia, Inc.Elutia, Inc.

Elutia, Inc.

No trades
See on Supercharts
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪136.17 M‬USD
−2.51USD
‪−43.66 M‬USD
‪24.75 M‬USD
‪19.47 M‬
Beta (1Y)
0.81
Employees (FY)
54
Change (1Y)
−110 −67.07%
Revenue / Employee (1Y)
‪458.24 K‬USD
Net income / Employee (1Y)
‪−763.87 K‬USD

About Elutia, Inc.


CEO
Charles Randal Mills
Website
Headquarters
Silver Spring
Founded
2015
FIGI
BBG00BRBB838
Elutia, Inc. operates as a biotechnology company. It develops biologic products to improve compatibility between medical devices and the patients who need them. The firm operates through the following segments: Device Protection, Women’s Health, Orthobiologics and Cardiovascular. The Device Protection segment includes biological envelope that remodels into systematically connected, vascularized tissue for the long-term pocket protection of certain cardiac and neurostimulator implantable electronic vehicles. The Women’s Health segment includes pre-hydrated, human acellular dermal matrix, or HADM, that is designed to enable rapid integration, cellular repopulation and rapid revascularization at the surgical site. The Orthobiologics segment includes a variety of viable matrices, produced with a proprietary process that is designed to protect and preserve native bone cells and reduce programmable cell death, for use in bone repair and fusion procedures. The Cardiovascular segment includes a portfolio of extracellular matrices that retain the natural composition of collagen, growth factors and proteins for use in vascular and cardiac repair and pericardial closure. The company was founded by Kevin L. Rakin and Charles Randal Mills on August 6, 2015 and is headquartered in Silver Spring, MD.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of ELUT is 3.86 USD — it has decreased by −2.03% in the past 24 hours. Watch Elutia, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Elutia, Inc. stocks are traded under the ticker ELUT.
ELUT stock has fallen by −20.25% compared to the previous week, the month change is a −2.53% fall, over the last year Elutia, Inc. has showed a 68.42% increase.
We've gathered analysts' opinions on Elutia, Inc. future price: according to them, ELUT price has a max estimate of 10.00 USD and a min estimate of 8.00 USD. Watch ELUT chart and read a more detailed Elutia, Inc. stock forecast: see what analysts think of Elutia, Inc. and suggest that you do with its stocks.
ELUT reached its all-time high on Jan 27, 2021 with the price of 18.20 USD, and its all-time low was 1.10 USD and was reached on Mar 22, 2023. View more price dynamics on ELUT chart.
See other stocks reaching their highest and lowest prices.
ELUT stock is 3.37% volatile and has beta coefficient of 0.81. Track Elutia, Inc. stock price on the chart and check out the list of the most volatile stocks — is Elutia, Inc. there?
Today Elutia, Inc. has the market capitalization of ‪136.18 M‬, it has increased by 14.29% over the last week.
Yes, you can track Elutia, Inc. financials in yearly and quarterly reports right on TradingView.
Elutia, Inc. is going to release the next earnings report on Feb 26, 2025. Keep track of upcoming events with our Earnings Calendar.
ELUT earnings for the last quarter are −0.69 USD per share, whereas the estimation was −0.44 USD resulting in a −56.26% surprise. The estimated earnings for the next quarter are −0.24 USD per share. See more details about Elutia, Inc. earnings.
Elutia, Inc. revenue for the last quarter amounts to ‪5.92 M‬ USD, despite the estimated figure of ‪6.60 M‬ USD. In the next quarter, revenue is expected to reach ‪6.40 M‬ USD.
ELUT net income for the last quarter is ‪1.07 M‬ USD, while the quarter before that showed ‪−28.18 M‬ USD of net income which accounts for 103.79% change. Track more Elutia, Inc. financial stats to get the full picture.
No, ELUT doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 30, 2024, the company has 54.00 employees. See our rating of the largest employees — is Elutia, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Elutia, Inc. EBITDA is ‪−20.80 M‬ USD, and current EBITDA margin is −68.81%. See more stats in Elutia, Inc. financial statements.
Like other stocks, ELUT shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Elutia, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Elutia, Inc. technincal analysis shows the sell today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Elutia, Inc. stock shows the buy signal. See more of Elutia, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.